MiNK Therapeutics Announces Strategic Collaboration with C-Further
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 10 2026
0mins
Should l Buy INKT?
MiNK Therapeutics announced a strategic collaboration with C-Further, an international pediatric oncology therapeutics consortium enabled by Cancer Research Horizons, LifeArc and Great Ormond Street Hospital Charity, to develop a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers. The collaboration between MiNK Therapeutics and C-Further will advance a T cell receptor-engineered invariant natural killer T cell therapy targeting PRAME, a tumor-associated antigen highly expressed across multiple pediatric and adult malignancies with limited expression in healthy tissues. By combining PRAME-specific antigen recognition with MiNK's iNKT cell platform, the program seeks to harness the biology of iNKT cells-immune effectors that bridge innate and adaptive immunity-to enable precise tumor targeting while also activating coordinated immune responses within the tumor microenvironment. Under the agreement, the MiNK program will receive approximately $1.1M in non-dilutive, aggregate funding to support IND-enabling development of its PRAME-TCR-iNKT asset, advancing the program through preclinical candidate nomination and key translational milestones, with payments tied to the completion of defined scientific milestones. The agreement also includes a double-digit share of downstream commercial revenues, reflecting the company's proprietary iNKT platform and its role in enabling next-generation TCR-based cellular therapies aligned with the objectives of the C-Further program. Importantly, the collaboration is non-exclusive, preserving MiNK's ability to continue advancing its iNKT platform independently and to pursue tumor antigen targets across oncology indications and partnerships. Under the collaboration, MiNK will serve as the lead industry partner, contributing its iNKT platform, engineering capabilities, and translational development expertise. Investigators at the University of Southampton will support independent, comparative preclinical studies to evaluate anti-tumor activity, persistence, and safety across multiple pediatric cancer models, including patient-derived tumor systems with the goal of nominating a single lead clinical candidate for advancement toward first-in-human studies in children.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INKT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INKT
Wall Street analysts forecast INKT stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.510
Low
35.00
Averages
35.00
High
35.00
Current: 10.510
Low
35.00
Averages
35.00
High
35.00
About INKT
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MiNK Therapeutics Q1 Earnings Beat Expectations
- Earnings Surprise: MiNK Therapeutics reported a Q1 GAAP EPS of -$0.57, beating expectations by $0.20, indicating an improvement in financial performance that could bolster investor confidence.
- Cash Position: As of Q1 2026, MiNK's cash and cash equivalents stood at approximately $9.5 million, down from about $13.4 million as of December 31, 2025, suggesting some pressure on the company's financial management.
- Clinical Development: MiNK plans to release initial ARDS Phase II data in H2 2026, which could provide critical support for the company's future product development and market positioning.
- Strategic Collaboration: The partnership with C-Further led to a 60% surge in MiNK Therapeutics' stock price, enhancing the company's market visibility and potentially laying the groundwork for expansion in the pediatric cancer sector.
See More
MiNK Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Progress: MiNK Therapeutics announced the initiation of a randomized Phase II clinical trial for acute lung injury in Q1 2026, with expectations for rapid early clinical data that supports its strategic development in pulmonary diseases.
- Strong Financial Position: As of the end of 2025, the company reported approximately $13.4 million in cash and cash equivalents, and after repaying $5.2 million in debt and raising $3 million, it ended the quarter with about $9.5 million, ensuring operational funding for at least the next 12 months.
- Partnership Strategy: The collaboration with C-Further aims to advance the PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers, providing nondilutive support and potential commercial economics, showcasing its strategic positioning in oncology treatment.
- Survival Rate Data: At the AACR meeting, MiNK reported Phase II data in gastroesophageal cancer, with a median overall survival exceeding 23 months in the immune-primed cohort, highlighting the treatment's potential and market prospects.
See More
Agenus Reports New Data on HCC Treatment
- Clinical Trial Results: Agenus' Phase 1b trial data reveals that in 19 patients with treatment-refractory hepatocellular carcinoma (HCC), the combination of BOT and BAL achieved an objective response rate of 17%, including one complete response and two partial responses, indicating potential efficacy in this challenging patient population.
- Survival Analysis: Among 18 efficacy-evaluable patients, the median overall survival was reported at 12.3 months, despite 47% of the cohort having ALBI grade 2 liver function, which typically indicates poorer prognosis, thus highlighting the potential of BOT and BAL in improving survival outcomes.
- Safety Assessment: The safety profile of BOT and BAL in HCC patients was consistent with prior studies, with 68% of patients experiencing immune-mediated adverse events and no treatment-related deaths, suggesting that the combination is manageable and suitable for further investigation.
- Future Research Directions: Investigators noted that the BOT and BAL combination demonstrated promising efficacy and manageable safety in post-immunotherapy HCC patients, supporting continued exploration in this area to assess its applicability in a broader patient population.
See More
MiNK Therapeutics Initiates Phase 2 Trial for agenT-797 in Severe Lung Injury
- Trial Initiation: MiNK Therapeutics has launched a randomized Phase 2 clinical trial for agenT-797, targeting severe acute lung injury and critical illness, with preliminary data expected in the second half of 2026, which will provide crucial insights for further development of the drug.
- Biological Rationale Strengthened: Presentations at AACR and ASGCT highlighted the durable survival and context-dependent activity of iNKT cells, particularly showing a 77% disease control rate and over 20 months of long-term survival in PD-1 refractory gastroesophageal cancer patients, underscoring its clinical potential.
- Capital Efficiency Improvement: MiNK secured approximately $1.1 million in non-dilutive funding through a collaboration with C-Further to advance a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers, a strategy that not only reduces capital burden but also offers potential downstream commercial revenue opportunities.
- Financial Update: As of Q1 2026, MiNK reported approximately $9.5 million in cash and cash equivalents, down from $13.4 million at the end of 2025, although net loss slightly decreased to $2.74 million, indicating the company's ongoing commitment to advancing high-priority clinical programs.
See More
MiNK Initiates iNKT Cell Therapy Trial for Acute Lung Injury
- Trial Launch: MiNK Therapeutics, in collaboration with First Lviv Medical Union, has initiated a randomized Phase 2 clinical trial in Lviv, Ukraine, to evaluate the efficacy of its iNKT cell therapy, agenT-797, in patients with acute lung injury, with preliminary data expected in the second half of 2026.
- Study Design: The trial is a randomized, placebo-controlled study aimed at assessing whether iNKT cell therapy can improve survival rates, ventilator-free days, and secondary infection control in critically ill patients, addressing a significant gap in effective treatments.
- Global Relevance: Acute lung injury and ARDS affect approximately 3 million people globally, with around 200,000 cases annually in the U.S., highlighting the clinical significance and potential market demand for this research on a global scale.
- Restoration of Immune Function: iNKT cells may restore immune coordination in critically ill patients by modulating immune responses, and MiNK believes this study will provide supportive data for future regulatory pathways in acute lung injury and related critical care conditions.
See More
MiNK Therapeutics' iNKT Therapy Shows Promise in Cancer and ARDS
- Therapeutic Efficacy: MiNK Therapeutics' agenT-797 demonstrated rapid IFN-gamma elevation in 34 solid tumor patients, indicating anti-tumor immune activation, while also producing IL-4 and IL-13 elevation in 20 ARDS patients, showcasing its potential for immune restoration across different disease states.
- Manufacturing Platform Advantage: The therapy's manufacturing platform isolates iNKT cells from the same donor batch and scales them to billions, ensuring intrinsic biological activity is preserved across various disease environments, thus supporting broad applications in acute critical care and oncology.
- Clinical Trial Outlook: MiNK plans to advance agenT-797 into a randomized Phase 2 trial for acute lung injury, with preliminary data expected in 2026, which will provide crucial evidence for further development and could transform existing treatment paradigms.
- Favorable Safety Profile: Immune activation observed in both oncology and ARDS patients occurred without uncontrolled cytokine release syndrome or pathological hyperinflammation, indicating a favorable therapeutic index that enhances the feasibility of clinical applications in intensive care settings.
See More
MiNK Therapeutics Q1 Earnings Beat Expectations
- Earnings Surprise: MiNK Therapeutics reported a Q1 GAAP EPS of -$0.57, beating expectations by $0.20, indicating an improvement in financial performance that could bolster investor confidence.
- Cash Position: As of Q1 2026, MiNK's cash and cash equivalents stood at approximately $9.5 million, down from about $13.4 million as of December 31, 2025, suggesting some pressure on the company's financial management.
- Clinical Development: MiNK plans to release initial ARDS Phase II data in H2 2026, which could provide critical support for the company's future product development and market positioning.
- Strategic Collaboration: The partnership with C-Further led to a 60% surge in MiNK Therapeutics' stock price, enhancing the company's market visibility and potentially laying the groundwork for expansion in the pediatric cancer sector.
See More
MiNK Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Progress: MiNK Therapeutics announced the initiation of a randomized Phase II clinical trial for acute lung injury in Q1 2026, with expectations for rapid early clinical data that supports its strategic development in pulmonary diseases.
- Strong Financial Position: As of the end of 2025, the company reported approximately $13.4 million in cash and cash equivalents, and after repaying $5.2 million in debt and raising $3 million, it ended the quarter with about $9.5 million, ensuring operational funding for at least the next 12 months.
- Partnership Strategy: The collaboration with C-Further aims to advance the PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers, providing nondilutive support and potential commercial economics, showcasing its strategic positioning in oncology treatment.
- Survival Rate Data: At the AACR meeting, MiNK reported Phase II data in gastroesophageal cancer, with a median overall survival exceeding 23 months in the immune-primed cohort, highlighting the treatment's potential and market prospects.
See More
Agenus Reports New Data on HCC Treatment
- Clinical Trial Results: Agenus' Phase 1b trial data reveals that in 19 patients with treatment-refractory hepatocellular carcinoma (HCC), the combination of BOT and BAL achieved an objective response rate of 17%, including one complete response and two partial responses, indicating potential efficacy in this challenging patient population.
- Survival Analysis: Among 18 efficacy-evaluable patients, the median overall survival was reported at 12.3 months, despite 47% of the cohort having ALBI grade 2 liver function, which typically indicates poorer prognosis, thus highlighting the potential of BOT and BAL in improving survival outcomes.
- Safety Assessment: The safety profile of BOT and BAL in HCC patients was consistent with prior studies, with 68% of patients experiencing immune-mediated adverse events and no treatment-related deaths, suggesting that the combination is manageable and suitable for further investigation.
- Future Research Directions: Investigators noted that the BOT and BAL combination demonstrated promising efficacy and manageable safety in post-immunotherapy HCC patients, supporting continued exploration in this area to assess its applicability in a broader patient population.
See More
MiNK Therapeutics Initiates Phase 2 Trial for agenT-797 in Severe Lung Injury
- Trial Initiation: MiNK Therapeutics has launched a randomized Phase 2 clinical trial for agenT-797, targeting severe acute lung injury and critical illness, with preliminary data expected in the second half of 2026, which will provide crucial insights for further development of the drug.
- Biological Rationale Strengthened: Presentations at AACR and ASGCT highlighted the durable survival and context-dependent activity of iNKT cells, particularly showing a 77% disease control rate and over 20 months of long-term survival in PD-1 refractory gastroesophageal cancer patients, underscoring its clinical potential.
- Capital Efficiency Improvement: MiNK secured approximately $1.1 million in non-dilutive funding through a collaboration with C-Further to advance a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers, a strategy that not only reduces capital burden but also offers potential downstream commercial revenue opportunities.
- Financial Update: As of Q1 2026, MiNK reported approximately $9.5 million in cash and cash equivalents, down from $13.4 million at the end of 2025, although net loss slightly decreased to $2.74 million, indicating the company's ongoing commitment to advancing high-priority clinical programs.
See More
MiNK Initiates iNKT Cell Therapy Trial for Acute Lung Injury
- Trial Launch: MiNK Therapeutics, in collaboration with First Lviv Medical Union, has initiated a randomized Phase 2 clinical trial in Lviv, Ukraine, to evaluate the efficacy of its iNKT cell therapy, agenT-797, in patients with acute lung injury, with preliminary data expected in the second half of 2026.
- Study Design: The trial is a randomized, placebo-controlled study aimed at assessing whether iNKT cell therapy can improve survival rates, ventilator-free days, and secondary infection control in critically ill patients, addressing a significant gap in effective treatments.
- Global Relevance: Acute lung injury and ARDS affect approximately 3 million people globally, with around 200,000 cases annually in the U.S., highlighting the clinical significance and potential market demand for this research on a global scale.
- Restoration of Immune Function: iNKT cells may restore immune coordination in critically ill patients by modulating immune responses, and MiNK believes this study will provide supportive data for future regulatory pathways in acute lung injury and related critical care conditions.
See More
MiNK Therapeutics' iNKT Therapy Shows Promise in Cancer and ARDS
- Therapeutic Efficacy: MiNK Therapeutics' agenT-797 demonstrated rapid IFN-gamma elevation in 34 solid tumor patients, indicating anti-tumor immune activation, while also producing IL-4 and IL-13 elevation in 20 ARDS patients, showcasing its potential for immune restoration across different disease states.
- Manufacturing Platform Advantage: The therapy's manufacturing platform isolates iNKT cells from the same donor batch and scales them to billions, ensuring intrinsic biological activity is preserved across various disease environments, thus supporting broad applications in acute critical care and oncology.
- Clinical Trial Outlook: MiNK plans to advance agenT-797 into a randomized Phase 2 trial for acute lung injury, with preliminary data expected in 2026, which will provide crucial evidence for further development and could transform existing treatment paradigms.
- Favorable Safety Profile: Immune activation observed in both oncology and ARDS patients occurred without uncontrolled cytokine release syndrome or pathological hyperinflammation, indicating a favorable therapeutic index that enhances the feasibility of clinical applications in intensive care settings.
See More
